

Gemini Stock Analysis Report

Based on the detailed analysis of the attached report for **CIPLA.NS**, here is my evaluation as a positional equity trader.

Step 1: Audit the Data

- **Data Present:**

- **Price Structure:** Daily, Weekly, and 15-minute candlestick charts with EMA overlays (20, 50, 200).
- **Trend Indicators:** MACD, Supertrend, ADX/DMI (implied via trend status).
- **Momentum/Oscillators:** RSI (14), Relative Strength (RS) vs. Benchmark, Bollinger Bands.
- **Volume:** Volume bars with Moving Averages, Distribution day counts.
- **Fundamentals:** Short-term and Long-term growth metrics (Revenue, EPS, ROE).

- **Data Missing:**

- **Order Flow:** Granular market depth/delivery percentage data (though volume analysis proxies this).
- **Sector Breadth:** Detailed performance of peer stocks beyond the CNXPHARMA index comparison.

- **Confidence Level: High.** The report provides a comprehensive technical and fundamental picture sufficient to make a risk-averse trading decision. *Note: The report date is simulated as January 24, 2026. Analysis is performed treating this as the "current" date.*

Step 2: Analyze the Setup

- **Price Structure & Trend:**

- The stock is in a **Strong Downtrend**. It is trading well below the 20, 50, and 200-day EMAs (Page 6).
- Price (1315) is roughly 12% below the 200 EMA (1499), indicating significant structural damage.
- The charts (Page 21) show a sharp vertical decline/gap-down, likely driven by the poor short-term fundamental data shown on Page 3 (Net Income -47.92% QoQ).

- **Momentum:**

- **RSI is at 15.79 (Page 16).** This is extremely oversold. While this often precedes a "dead cat bounce," deeply oversold readings (<20) confirm intense bearish momentum rather than a safe entry point for a positional hold.
- **MACD (Page 13): Bearish** crossover with the histogram expanding downwards, confirming strengthening bearish momentum.

- **Relative Strength:**

- RS Score is 45.1/100 and the trend is "Not Improving" (Page 4). The stock is severely underperforming its sector.

- **Volume:**

- Volume analysis indicates heavy "Distribution" (Page 18). The recent sharp drop is accompanied by high volume, suggesting institutional exit.

Confluence Check: There is **zero bullish confluence** for a positional trend trade. While the Bollinger Bands signal a "Buy" (Page 8), this is strictly a mean-reversion signal (price outside bands) and is highly dangerous to trade in the face of collapsing fundamentals and trend structure.

Step 3: Formulate the Recommendation

Recommendation: **NO** (Do Not Enter).

Reasoning: Trying to enter CIPLA.NS now is "catching a falling knife." A positional trade requires an

Gemini Stock Analysis Report

established trend or a completed base. CIPLA has neither; it is in price discovery mode to the downside. The probability of a 5-15% sustained upside is low compared to the risk of continued capitulation. The fundamental deterioration (EPS down ~48%) validates the price crash, suggesting the market is repricing the stock lower.

Conditional Plan (Watchlist for Reversal): I would only consider this stock for a positional long once the selling climax completes and a "floor" is established.

- **Condition to Buy:**

1. Price must stop making lower lows on the Daily chart.
 2. RSI must recover above 30 and show bullish divergence.
 3. **Crucial Trigger:** Price must Close above the **20-day EMA** on the Daily chart (currently near 1428, but it will slope down rapidly to meet price). This confirms the immediate selling pressure has abated.
- **Entry Price (Hypothetical):** ~1380 - 1400 (Assumes the 20 EMA drops to this level and price reclaims it after consolidation).
 - **Stop Loss (Hypothetical):** ~1250 (Placing it below the swing low formed during the consolidation).
 - **Take Profit (Hypothetical):**
 - Target 1: 1470 (50-day EMA resistance).
 - Target 2: 1500 (200-day EMA and breakdown retest level).

News & Analyst Targets

The following is a research summary for **Cipla Limited (CIPLA)** for the week ending **January 25, 2026**.

1) Latest News for CIPLA This Week

The most significant event this week was the announcement of **Q3 FY26 financial results**, which were below market expectations.* **Q3 FY26 Earnings Miss (Jan 23):** Cipla reported a **57% year-on-year drop** in consolidated net profit to **INR 676 crore** (vs. INR 1,571 crore in Q3 FY25). This was significantly lower than analyst estimates (consensus was ~INR 1,242 crore).* **Revenue Performance:** Revenue from operations remained flat at **INR 7,074 crore**.* **Profitability Hit:** EBITDA fell **37% YoY** to INR 1,255 crore, with margins contracting to 17.7% (down from 26.5% a year ago).* **One-time Impact:** The company incurred a one-time cost of INR 276 crore related to a new labor code, further impacting the bottom line.* **Key Management Personnel:** The board approved the re-appointment of Mr. P.R. Ramesh as Independent Director and announced changes in Key Managerial Personnel effective April 1, 2026.

2) Brokerage Upgrades & Downgrades

The sentiment has turned cautious to negative following the Lanreotide supply issue and weak Q3 results.* **Downgrades:** * **Nuvama:** Downgraded the stock to "**Reduce**" (from Hold) earlier in the week/late last week, citing poor earnings visibility due to supply disruptions. * **Morgan Stanley:** Maintained an "**Underweight**" rating, lowering their price target. * **MarketsMOJO:** Downgraded the stock to "**Sell**" on Jan 19 due to bearish technicals and negative financial trends.* **Maintained/Positive:** * **Nomura:** Maintained a "**Buy**" rating (as of mid-Jan), viewing the dip as a potential entry point, though risks remain. * **Systematix Shares:** Issued a fresh "**Buy**" recommendation on Jan 19.

Gemini Stock Analysis Report

3) Other News Impacting CIPLA

- **Lanreotide Supply Disruption (Major Impact):** The primary reason for the Q3 miss and stock decline is the temporary halt in production of *Lanreotide* (a key cancer drug) by Cipla's European partner, Pharmathen.
 - **USFDA Observations:** The partner's facility in Greece received **9 observations** (Form 483) from the USFDA.
 - **Timeline:** Cipla expects supply to resume only in **H1 FY27**, meaning sales will be impacted for the next several quarters. US Revenue in Q3 already dropped to \$167M (vs \$233M in Q2).
- **Acquisitions:** To diversify, Cipla paid **INR 11 billion** to Novartis for rights to manufacture and market diabetes drugs (Galvus range) and acquired **Inzpera Healthscience** for INR 1.1 billion to boost its consumer healthcare and pediatric portfolio.

4) Analyst Price Targets (January 2026)

Below is a summary of the latest targets from major brokerages. Note that some targets were revised specifically due to the Lanreotide news just prior to the Q3 results.

Brokerage Firm	Rating	Target Price (INR)	Sentiment	Date / Context
Nomura	Buy	1,770	Bullish	Jan 16 (Maintained post-Lanreotide news)
Systematix	Buy	1,681	Bullish	Jan 19
Jefferies	Hold	1,630	Neutral	Jan 07 (Pre-Lanreotide halt news)
Nuvama	Reduce	1,360	Bearish	Jan 16 (Downgraded from Hold)
Morgan Stanley	Underweight	1,292	Bearish	Jan 16 (Target cut from INR 1,300+)

Current Market Price (approx. close Jan 23, 2026): INR 1,315 - INR 1,330**


Stock Detailed Analysis Report

CIPLA.NS

Current Price: ₹1315.00

Generated: 2026-01-24 18:26

CIPLA.NS - 3 Year Daily Price Chart



Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	No	6.68%	7.88%
Net Income	Yes	No	27.93%	27.96%
ROE	Yes	No	9.52%	11.86%
EPS	Yes	No	27.89%	27.91%

Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	1.84%	0.06%
Net Income	No	-47.92%	-10.84%
ROE	No	-14.71%	-14.71%
EPS	No	-47.92%	-5.57%

CIPLA.NS - Relative Strength Analysis

== OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	Neutral
RS Score:	45.1/100
:	

== RS RATIOS ==:

1M RS:	0.928 [Neutral]
3M RS:	0.869 [Neutral]
6M RS:	0.890 [Neutral]
1Y RS:	0.934 [Neutral]
:	


== TURNAROUND ANALYSIS ==:

Turnaround Status:	Not Detected
:	


SIGNAL CRITERIA::

✓ Emerging RS:	1M (0.928) > 3M (0.869)
✓ Medium-term Lagging:	6M=0.890, 1Y=0.934 (≤ 1.0)
✗ Performance Improving:	Not improving


Relative Strength Analysis: CIPLA.NS vs ^CNXPHARMA
Classification: Neutral
Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)



RS Composite Score Timeline



CIPLA.NS - EMA Crossover Summary


EMA 20: 1428.75

EMA 50: 1472.50

EMA 200: 1499.28

Trend Status: **Strong Downtrend**


CIPLA.NS EMA Crossover Analysis



CIPLA.NS - Bollinger Bands Summary

Current Price:	1315.00
Upper Band:	1568.43
Middle Band (SMA 20):	1448.04
Lower Band:	1327.65
%B:	-0.0526
Band Width:	0.1663
Status:	Below Lower Band
Signal:	Buy Signal
Recent Signal 1:	Buy Signal at 2026-01-20 00:00:00+05:30
Recent Signal 2:	Buy Signal at 2026-01-21 00:00:00+05:30
Recent Signal 3:	Buy Signal at 2026-01-23 00:00:00+05:30

CIPLA.NS Bollinger Bands (20, 2) Analysis




CIPLA.NS - Supertrend Summary

Status: DOWNTREND (Sell)

Supertrend Value: 1440.60

Signal Identified On: 2025-10-28


Supertrend Analysis for CIPLA.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




CIPLA.NS - MACD Summary

MACD Line:	-40.00
Signal Line:	-26.92
Histogram:	-13.09
Trend:	Bearish
Momentum:	Strengthening
Signal:	None

CIPLA.NS Price






CIPLA.NS MACD (12, 26, 9)



CIPLA.NS - Volatility Squeeze Summary

BB Width:	0.1663
ATR:	32.0500
Total Signals:	38
Signal 1:	BB Squeeze + ATR Contraction at 2025-12-31 00:00:00+05:30 (Pr)
Signal 2:	BB Squeeze + ATR Contraction at 2026-01-01 00:00:00+05:30 (Pr)
Signal 3:	BB Squeeze + ATR Contraction at 2026-01-02 00:00:00+05:30 (Pr)
Signal 4:	BB Squeeze + ATR Contraction at 2026-01-05 00:00:00+05:30 (Pr)
Signal 5:	BB Squeeze + ATR Contraction (Bullish Breakout) at 2026-01-06 00:00:00+05:30 (Pr)




CIPLA.NS - Volatility Squeeze Analysis



CIPLA.NS - RSI-Volume Summary

Current RSI:	15.79
Current Volume:	6590032
Volume MA 20:	2117608
Bullish Divergences:	0
Bearish Divergences:	4
Bearish Div 1:	Date: 2024-10-09 00:00:00+05:30, Price: 1662.74
Bearish Div 2:	Date: 2025-08-25 00:00:00+05:30, Price: 1601.20

CIPLA.NS RSI-Volume Divergence Analysis



CIPLA.NS - Volume Analysis

== VOLUME ANALYSIS ==:

Status: 45 Signals Detected

:

2026-01-13 [-]: Distribution Day



2026-01-14 [-]: Distribution Day

2026-01-19 [-]: Distribution Day

2026-01-20 [-]: Distribution Day

2026-01-21 [-]: Distribution Day

CIPLA.NS - Volume Analysis




Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	DOWNTREND (Sell)	1472.27	1315.0	2026-01-05
1 Day	DOWNTREND (Sell)	1440.6	1315.0	2025-10-28
15 Min	DOWNTREND (Sell)	1343.76	1323.0	2026-01-23

Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	Bearish	Strengthening	No Signal
1 Day	Bearish	Strengthening	No Signal
15 Min	Bearish	Weakening	No Signal

CIPLA.NS - 1 Week (Candlestick + EMAs)



CIPLA.NS - 1 Day (Candlestick + EMAs)



CIPLA.NS - 15 Min (Candlestick + EMAs)



Trendlyne Snapshot - CIPLA_main

Markets STARFOLIO Alerts F&O MF Reports Screeners [Subscribe](#) Superstars Portfolio Watchlist Insider Trades Results Data Downloader More [More](#) A

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / [CIPLA LTD.](#)

Cipla Ltd. [①](#)

NSE: CIPLA | BSE: 500087
Cipla Live Share Price Today, Share Analysis and Chart

Mid-range Performer [①](#) In 7 Starfolio Baskets

1315.00 -55.40 (-4.04%) [↓ New 52W Low today](#)

7.1M NSE+BSE Volume [High volume today](#)
NSE 23 Jan, 2026 3:31 PM (IST)

[Watchlist](#) [Portfolio](#) [Alert](#) [My Notes](#) [TRADE STOCK](#)

[Estimates Miss](#) Cipla's Q3 net profit and revenue miss Forecaster estimates by 46.1% and 6.5%, respectively [See details](#)

[Overview](#) [FORECASTER](#) [STOCK REPORT](#) [Buy Sell Zone](#) [F&O](#) [Financials](#) [News](#) [Reports](#) [Technicals](#) [Shareholding](#) [Deals](#) [Corporate Actions](#) [Alerts](#) [About](#)

Durability score [①](#) **55.0 /100** Valuation Score [①](#) **36.7 /100** Momentum Score [①](#) **36.2 /100** Analyst Price Target [①](#) **1,605**

Medium Financial Strength Mid Valuation Technically Neutral

[Mid-range Performer](#) These stocks have average quality, financial and technical momentum, indicating a mid range performer [View Similar](#) [Embed DVM](#)

14 **13**
3 **4**
[SWOT Analysis](#)

Check Before You Buy [VIEW FULL CHECKLIST](#)
High rank **14** Positive 9 Negative
60.9% Pass in checklist

PE Valuation Check
Right Now [①](#) Undervalued **30.4%** 1 Year Forward [①](#) Undervalued **19.4%**

INSIGHT Cipla is undervalued at both current PE and future earnings estimates.

Preset Metrics [Preset Metrics](#)

Cipla Key Metrics

Key Metrics: DVM, Key Metrics, Price Chart, Forecaster, Financials, Technicals, Shareholding, Deals, Documents, Corporate actions, Company Profile

Trendlyne Snapshot - CIPLA_forecaster

Markets STARFOLIO Alerts F&O MF Reports Screeners [Subscribe](#) Superstars Portfolio Watchlist Insider Trades Results Data Downloader More [More](#)

Search Stock, IPO, MF [India](#) A

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / [CIPLA LTD.](#)

Cipla Ltd. ⓘ

NSE: CIPLA | BSE: 500067

Mid-range Performer ⓘ In 4 Starfolio Baskets

1315.00 -55.40 (-4.04%)

↓ New 52W Low today

7.1M NSE+BSE Volume ⓘ High volume today

NSE 23 Jan, 2026 3:31 PM (IST)

Watchlist Portfolio Alert My Notes [TRADE STOCK](#)

Estimates Miss Cipla's Q3 net profit and revenue miss Forecaster estimates by 46.1% and 6.5%, respectively See details


Overview FORECASTER STOCK REPORT Buy Sell Zone F&O Financials News Reports Technicals Shareholding Deals Corporate Actions Alerts About

Cipla - CIPLA - stock price prediction, stock forecast, target price, analyst ratings from 36 analysts

Cipla has a share price target of Rs 1641, revenue growth forecast of 6.2%, and profit growth estimate of -7.0% for FY26, based on top 36 analyst calls.

Cipla FORECASTER - Analyst Estimates ⓘ

[FORECASTER DASHBOARD →](#)



BUY

CONSENSUS RECOMMENDATION

36 ANALYST Recommendations

Rating	Buy	Hold	Sell	Strong Sell	Date
15	8	7	3	3	Aug '25
15	7	8	3	3	Sep '25
16	6	7	3	3	Oct '25
13	8	7	5	2	Nov '25
12	8	9	5	2	Dec '25
12	8	7	6	3	Jan '26

● STRONG BUY ● BUY ○ HOLD ● SELL ● STRONG SELL